Abstract
Targeting of PP2A suggests a close link to tau-related cognitive and functional declines. However, little is known about how the expression of PP2A subunits and PP2A activity are dysregulated in the course of AD, precluding any specific targeting strategy for restoring PP2A in AD patients. Although the PP2A heterotrimer containing the regulatory subunit PR55/Bα (encoded by the PPP2R2A gene) is the major tau phosphatase, the involvement of other brain-specific PP2A regulatory subunits in tau dephosphorylation remains unknown. PR55/Bγ (encoded by the PPP2R2C gene) is a pivotal phosphatase in the brain, and single-nucleotide polymorphisms (SNPs) of PPP2R2C are involved in several mental disorders. By measuring the differential spatiotemporal expression patterns of PPP2R2C in Wt and transgenic AD mice, we revealed that PPP2R2C expression is downregulated in the aged AD mouse brain as compared to the Wt mouse brain. In cultured cells, PPP2R2C expression regulates PP2A activity and tau dephosphorylation. These results suggest that dysregulation of PPP2R2C expression may be involved in the onset of AD and that specifically targeting PPP2R2C expression or activity is a promising strategy against brain dementia disorders, including AD and other tauopathies.
Highlights
Dementia is a growing global health and social burden due to large aging populations
PPP2R2C expression regulates PP2A activity and tau dephosphorylation. These results suggest that dysregulation of PPP2R2C expression may be involved in the onset of Alzheimer’s disease (AD) and that targeting PPP2R2C expression or activity is a promising strategy against brain dementia disorders, including AD and other tauopathies [10,11,12,13]
We further addressed the mechanism through which PPP2R2C regulates PP2A activity
Summary
Dementia is a growing global health and social burden due to large aging populations. Alzheimer’s disease (AD) is responsible for 50–60% of dementia cases [1]. AD is a chronic neurodegenerative disorder characterized by progressive memory loss and inability to form new memories. More than 25 million individuals are living with AD worldwide, and this number doubles every 20 years. There are two histopathological hallmarks of AD: accumulation of amyloid plaques comprised of multiple forms of Aβ deposits, and neurofibrillary tangles of aggregated phosphorylated tau proteins [2, 3]. After numerous failures of Aβ-targeting drugs for AD, interest is growing in the therapeutic potential of targeting tau [4]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have